Immunex Corporation

US Government As Represented by the Secretary of the Army

Cornell Research Foundation Inc.

Innunex Corporation

Charles R Maliszewski

Douglas Pat Cerretti

Brian S Davis

David Haskett Lynch

Luis G Borges

Michael A Schoenborn

David J Cosman

Eugene Maraskovsky

Hilary Jean McKenna

Kenneth Allan Brasel

Richard B Gayle, Iii

Paul E Baker

Fred D Finkelman

Robert E Miller

Aaron J Marcus

William R Clevenger

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

Methods of using flt3-ligand in the treatment of fibrosarcoma

The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.

Methods of inhibiting platelet activation and recruitment

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

Methods of preparing dendritic cells with flt3-ligand and antigen

The biological activity of exogenous ligand proteins is enhanced by intravenously co-administering to a mammal the ligand and a soluble receptor protein that binds thereto. Pharmaceutical compositions comprising a ligand protein complexed with a soluble receptor protein are provided. In certain embodiments, the ligand is selected from the group consisting of interleukins, colony stimulating factors, and tumor necrosis factor.

Pharmaceutical compositions comprising a soluble interleukin-4 receptor

Cloning and expression of nucleotide DNA segments encoding bovine IL-1.beta., and processes for producing purified bovine IL-1.beta. as a product of recombinant cell culture, are disclosed.

Bovine interleukin-1.beta. protein and amino acid sequence

The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.

IgA Fc receptors

Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.

Bovine interleukin-1.alpha.

DNA encoding IgA Fc receptors

A process for preparing bovine interleukin I.beta. (bIL-1.beta.) by culturing a microbial host transformed by a vector containing a DNA sequence encoding bIL-1.beta. under conditions suitable for the expression of bIL-1.beta. and recovering bIL-1.beta..

Process for preparing bovine interleukin-I.beta.

Cloning and expression of DNA segments encoding bovine GM-CSF, and processes for producing recombinant bovine GM-CSF as a product of recombinant cell culture, are disclosed.

Bovine granulocyte-macrophage colony stimulating factor

Cloning and expression of DNA segments encoding bovine IL-.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.

Growing community of inventors

Seattle, WA, United States of America

Charles R Maliszewski